Compare Incyte Corporation (INCY) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Match Group Inc — how do they compare? Incyte Corporation trades at $113.16 (market cap $22.85B), while Match Group Inc trades at $41.27 (market cap $9.53B). The key difference: Incyte Corporation is far larger — about 2.4× Match Group Inc's market cap, and Match Group Inc pays a 1.93% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Match Group Inc for 115 Days on average.
| INCY | MTCH | |
|---|---|---|
Market Cap | $22.85B | $9.53B |
Volume | 1,927,029 | 3,228,794 |
Sector | Health | Media |
52-Week High | $129.93 | $44.40 |
52-Week Low | $83.80 | $28.90 |
Typical Hold Time | 33 Days | 115 Days |
Enterprise Value | $18.35B | $12.49B |
Dividend Yield | — | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
MTCH trades at $41.48, up 1.52% today, near the consensus price target of $42.29. The stock shows a bullish technical trend with strong moving averages, though RSI indicates potential overbought conditions. Fundamentally, the company maintains robust profitability with a 20.17% net income margin and positive cash flow trends, while recent earnings have been mixed with a beat in Q2 2026 but a miss in Q1 2026. Positive sentiment is driven by product innovation at Tinder and growth from Hinge.
The outlook for MTCH is positive, supported by analyst consensus leaning buy (53% of ratings) and a projected EPS beat in Q3 2026. Investment opportunities include margin expansion and AI-driven product enhancements, but risks involve high debt levels and competitive pressures in the dating app market. Shareholder value may benefit from sustained cash flow generation and strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
